Amyloid-beta protein (Ab) and the scrapie isoform of prion protein (PrP Ss ) have a central role in the pathogenesis of Alzheimer's disease (AD) and prion-related encephalopathies (PRE), respectively. In both disorders, the deposition of these misfolded proteins is accompanied by apoptotic neuronal loss. However, the pathogenesis and molecular basis of Ab-and PrP Sc -neurotoxic effects are not completely understood. The Ca 2+ / calmodulin-dependent phosphatase calcineurin (CaN), through the dephosphorylation of the proapoptotic protein BAD, may be the link between Ca 2+ homeostasis deregulation and apoptotic neuronal death. In this study we used primary cultures of rat brain cortical neurons in order to investigate whether Ab and PrP affect CaN activity. We observed that synthetic peptides of Ab (Ab 25-35 and Ab 1-40 ) and PrP (PrP 106-126 ) increased CaN activity, but did not affect the levels of this protein phosphatase. Moreover, we found that these peptides reduced the levels of BAD phosphorylated at serine residue 112, and this effect was prevented by the CaN inhibitor FK506. Since dephosphorylated BAD translocates to mitochondria, where it triggers cytochrome c release, we determined the levels of BAD in mitochondrial and cytosolic fractions. The data obtained showed that Ab-and PrP-treated neurons had higher levels of BAD in mitochondria than control neurons. This increase in mitochondrial BAD levels was matched by a decrease in cytochrome c. FK506 prevented the alterations of mitochondrial BAD and cytochrome c levels induced by Ab and PrP peptides. Taken together the data suggest that Ab and PrP increased CaN activity, inducing BAD dephosphorylation and translocation to mitochondria and, subsequently, cytochrome c release that may trigger an apoptotic cascade. Therefore, therapeutic strategies targeting CaN might be valuable for these neurodegenerative disorders. #
Introduction
The abnormal accumulation of proteins is a pathological feature in Alzheimer's disease (AD) and prion-related encephalopathies (PRE). The key pathogenic event in AD and PRE is linked to a conformational change of normally expressed proteins: the amyloid-beta (Ab) and the cellular prion protein (PrP C ). Ab is a 40-42 amino acid peptide that derives from the proteolytic cleavage of amyloid precursor protein (APP) mediated by b-and g-secretases (Marks and Berg, 2008) . This peptide self-assembles into toxic oligomers and fibrils that accumulate in the brain of AD patients, forming amyloid plaques. The PrP C is a cell membrane glycoprotein that can undergo disease-associated structural modifications, giving rise to a pathogenic isoform called scrapie prion protein (PrP Sc ) that accumulates as amyloid plaques in the brain of patients suffering from PRE (Barnham et al., 2006; Wisniewski and Sigurdsson, 2007) . Recently, it was proposed that the Cterminal of a-helices in PrP C refolds into b-strands, which adopt a parallel alignment (Cobb et al., 2007) . Both Ab and PrP Sc have a high b-sheet content, which renders them insoluble, resistant to proteolysis and neurotoxic (Soto, 1999; Wisniewski and Sigurdsson, 2007) . The involvement of these amyloidogenic proteins in disease was validated by the finding that mutations in genes that codified APP and PrP C result in autosomal-dominant AD and PRE (Carter, 2007; Aguzzi and www.elsevier.com/locate/neuint Haass, 2003) . These neurodegenerative disorders are characterized by memory and cognitive deficits that occur as a consequence of neuronal dysfunction and death, which are attributable, in part, to the gradual deregulation of neuronal Ca 2+ homeostasis (LaFerla, 2002; Kawahara, 2004; Demuro et al., 2005) . A neuroinflammatory process, characterized by microglia activation, is also involved in AD and PRE pathogenesis (Wisniewski and Sigurdsson, 2007) . Currently, the development of anti-Ab immunotherapeutic approaches that can also modulate microglial activation is a huge challenge for AD treatment (Morgan, 2006) .
Calcineurin (CaN) is a serine/threonine phosphatase physiologically activated by Ca 2+ and calmodulin that exists at high levels in neurons, accounting for 1% of the total protein. This unique Ca 2+ -activated protein phosphatase, also named as phosphatase 2B, links Ca 2+ to the dephosphorylation of several targeted molecules, such as proapoptotic factors, transcription factors and ion channels. Moreover, CaN has been shown to play a role in learning and memory processes, as well as in apoptosis of neuronal cells (Mansuy, 2003; Hara and Snyder, 2007) . As a consequence of an insult that increases cytosolic Ca 2+ concentration, such as Ab or PrP peptides exposure and aging (Agostinho and Oliveira, 2003; Mattson, 2006) , the Ca 2+ -activated CaN can trigger apoptosis through the dephosphorylation of Bcl 2 -associated death protein (BAD). This proapoptotic protein exists normally in the cytosol bounded to the 14-3-3 protein and phosphorylated on serine residues, mainly serine 122 (S112), S136 and S155 (Springer et al., 2000) . After an insult, BAD is dephosphorylated and translocates from the cytosol to mitochondria. In the outer cell membrane of mitochondria, BAD interacts and inhibits the actions of the anti-apoptotic proteins Bcl-2 and Bcl-x L , promoting the release of cytochrome c (cyt c) that leads to the activation of the postmitochondrial caspase apoptotic cascade (Wang et al., 1999; Springer et al., 2000; Kim et al., 2006) .
The purpose of this study is to investigate whether the synthetic peptides Ab 25-35 , Ab 1-40 and PrP , which mimic the toxic effects of Ab and PrP Sc (Agostinho and Oliveira, 2003; Ferreiro et al., 2006) , change the functional role of CaN. We have observed that Ab and PrP peptides increased the activity of this phosphatase in rat brain cortical neurons, leading to BAD dephosphorylation and translocation to mitochondria. The data obtained suggest that the neurotoxic effects triggered by Ab and PrP peptides were partially due to changes in CaN activity and, subsequent, alterations in phosphorylation state of BAD.
Experimental procedures

Reagents
Neurobasal medium and B-27 supplement were purchased from GIBCO (Paisley, UK). Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , Ab 1-40 and PrP were from Bachem (Bubendorf, Switzerland). The mouse anti-calcineurin1 (clone 29) and the mouse anti-BAD (clone 48) antibodies were obtained from BD Biosciences (Erembodegem, Belgium), whereas the phosphospecific antibody against BAD phosphorylated at serine 112 (pS112-BAD) was from Biosource (Nivelles, Belgium). The monoclonal antibody against the denatured form of cyt c (clone 7H8.2C12) was acquired from PharMingem (San Diego, CA, USA), whereas the anti-actin monoclonal antibody (clone AC-40) was from Sigma (St. Louis, MO, USA). Serine/threonine phosphatase assay kit was obtained from Promega (Madison, WI, USA). Reagents and apparatus used in Western blot assays were obtained from Bio-Rad (Hercules, CA, USA), whereas PVDF membranes, alkaline phosphatase-linked anti-mouse secondary antibody and the enhanced chemifluorescence (ECF) reagent were from Amersham Biosciences (Buckinghamshire, UK). MitoTracker-green, Alexafluor 594 anti-mouse IgG conjugate and Antifade kit were obtained from Molecular Probes (Leiden, Netherlands). All other reagents were from Sigma Chemical Co. (St. Louis, MO, USA).
Cultures of rat brain cortical neurons
Primary cultures of cortical cells were prepared from 15-16 days embryos of Wistar rats according to the method previously described by Agostinho and Oliveira (2003) . Cortical cells were cultured in Neurobasal medium added on with 2 mM L-glutamine, 2% B27 supplement, penicillin (100 U/ml) and streptomycin (100 mg/ml). The neurons were cultured on poly-L-lysine (0.1 mg/ml) coated plates at a density of 0.2 Â 10 6 cells/cm 2 , and maintained at 37 8C in a humidified atmosphere of 5% CO 2 /95% air.
Cells treatments
Cultured cortical neurons were treated with 25 mM Ab 25-35 , 1 mM Ab 1-40 or 25 mM PrP 106-126 , for 24-48 h. The peptides were added to culture medium at the 4-5th culturing day. FK506 (1 mM) was added just before the peptides.
Preparation of cell lysates and fractions
Treated cortical cells were lysed with ice-cold isolation buffer (250 mM sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM MgCl 2 (pH 7.4), 1 mM DTT, 1 mM PMSF and protease inhibitor cocktail). The cell lysates used to measure the levels of phospho-BAD by Western blot were prepared in the isolation buffer containing 1 mM sodium orthovanadate and 5 mM sodium pyrophosphate, 50 mM sodium fluoride. The cell lysates were rapidly frozen/defrosted three times, and cleared by centrifugation (20,200 Â g for 10 min) before colleting the supernatant. Mitochondrial and cytosolic fractions were prepared, as described previously in Agostinho and Oliveira (2003) . Bio-Rad protein dye assay reagent was used to determine protein concentration in the samples.
Calcineurin activity
The activity of CaN was determined using a serine/threonine phosphatase assay Kit from Promega (V2471), according to the manufacture's instruction. In brief, cell lysates (prepared as described above) were first centrifuged at 100,000 Â g for 1 h (4 8C) to remove contaminating components, such as ATP and free endogenous phosphate from samples. After spin columns preparation, accordingly with the instructions of the kit, 250 ml of cell lysates were added on each column. The cell lysates were then centrifuged at 600 Â g for 5 min (4 8C) and the samples collected from the bottom of the reservoir. The collected samples (5 mg protein) and standards of free phosphate (0-2000 pmol) were incubated with the phosphopeptide substrate in the presence of a reaction buffer specific for phosphatase 2B (250 mM imidazole, 1 mM EGTA, 50 mM MgCl 2 , 5 mM NiCl 2 , 250 mg/ml calmodulin, 0.1% bmercaptoethanol), during 5 min. Then the reaction was stopped by adding molybdate dye/additive mixture and after 15 min at room temperature, the absorbance was measured at 600 nm in a plate reader.
Western blot assay
Samples containing an equal amount of total protein were loaded on 15% SDS-polyacrylamide gels. To facilitate the further identification of proteins a pre-stained precision protein standard (Bio-Rad) was used. The proteins of samples were separated by electrophoresis and transferred electrophoretically to PVDF membrane (Agostinho and Oliveira, 2003) . These membranes were blocked using a Tris-buffered solution (150 mM NaCl, 25 mM Tris-HCl, pH 7.6) containing 0.1% Tween-20 (TBS-T) and 5% bovine serum albumin (BSA) for 1 h at room temperature. Incubation with the primary antibodies (anti-calcineurin 1:250, anti-actin 1:1000, anti-BAD 1:500, anti-pS112-BAD 1:500, anti-cyt c 1:500 in TBS-T 1% BSA) was performed overnight at 4 8C. After extensive washing, the membranes were incubated with phosphataselinked specific secondary antibodies (1:25000). Bands of immunoreactive proteins were visualized, after membrane incubation with enhanced chemifluorescence (ECF) reagent for 5 min, on a Storm 860 Gel. Densities of blot bands were calculated using the Blot Imaging System (Amersham Pharmacia Biotech).
Immunocytochemistry
Cultured cortical neurons were treated with the peptides in the absence or presence of FK506 and then were processed as described previously by Agostinho and Oliveira (2003) . In brief, the cells were incubated with MitoTracker green for 45 min at 37 8C, and after being washed with PBS to remove the excess of fluorescence probe, they were fixed with 4% paraformaldehyde for 15 min. Then, the cells were incubated with 20 mM glycine (in PBS) for 15 min and subsequently permeabilized with 0.1% saponin (in PBS) for 30 min at room temperature. Afterwards the cells were incubated with: (i) anti-BAD antibody (1:500) for 2 h and (ii) Alexa Fluor goat anti-mouse IgG antibody (1:100). Finally, the cells were mounted on microscope glass, using Prolong Antifade kit, and examined by confocal microscopy (Bio-Rad MRC 600).
Results
In a previous study we have demonstrated that the inhibitor of CaN, FK506, prevents cyt c release and the subsequent caspase-3 dependent apoptotic cell death induced by Ab and PrP synthetic peptides (Agostinho and Oliveira, 2003) , suggesting that CaN is involved in neuronal death caused by these peptides. Therefore, in the present study we investigated the effect of Ab and PrP peptides in CaN activity and levels, as well as in the phosphorylation state of the CaN target, BAD (Wang et al., 1999) . The concentrations and incubation time period used for Ab and PrP synthetic peptides treatments were chosen based on previous studies made at our lab (Agostinho and Oliveira, 2003; Ferreiro et al., 2006) .
The activity of CaN was evaluated in cortical neurons treated with Ab 25-35 (25 mM), Ab 1-40 (1 mM) or PrP 106-126 (25 mM) peptides by measuring the formation of free phosphate (PO 4 ), using a specific kit assay (see material and methods section). Fig. 1 (Fig. 1) . The CaN inhibitor FK506 (Snyder et al., 1998) almost completely prevented PO 4 formation in cells untreated or treated with the peptides (Fig. 1B) , what reinforces that we were determining the activity of this phosphatase. These data suggest that CaN activity was significantly increased by Ab 25-35 , Ab 1-40 or PrP 106-126 peptides. In order to clarify whether the increase in CaN activity, induced by Ab and PrP peptides, reflects an increase in phosphatase levels, we further determined the levels of this protein by Western blot. The data showed that CaN levels in control cells were similar to those found in cells treated with Ab 25-35 , Ab 1-40 or PrP (Fig. 2) , indicating that Ab and PrP peptides did not affect the levels of this protein phosphatase.
Since BAD, which is normally phosphorylated on serine residues, is one of the substrates of CaN (Springer et al., 2000) we determined the phosphorylation state of this proapoptotic protein in neurons untreated or treated with Ab and PrP peptides, using a phospho specific antibody that labels BAD phosphorylated at serine 112 (pS112-BAD). Ab 25-35 , Ab 1-40 or PrP 106-126 peptides significantly ( p < 0.05) decreased the levels of pS112-BAD by about 30% as compared with control cells (Fig. 3) . FK506 partially prevented the decrease in pS112-BAD levels induced by Ab and PrP peptides. To ensure that changes in the relative levels of phosho-BAD were not due to differences in the amount of total BAD, we also determined the levels of this protein using an antibody that recognizes BAD independently of its phosphorylation state. The data obtained show that neither Ab nor PrP peptides affected the total BAD levels in neuronal cell lysates (Fig. 3B) .
Dephosphorylated BAD translocates to mitochondria and promotes cytochrome c (cyt c) release from this organelle (Wang et al., 1999; Kim et al., 2006) . Therefore, to provide additional evidence that Ab and PrP peptides increase CaN and subsequently BAD dephosphorylation, we determined the levels of BAD in the mitochondrial fractions of neurons treated with Ab and PrP peptides. Since the results obtained with Ab 1-40 in CaN activity and cellular BAD levels were . After 24 h incubation, the neurons were lysed and the protein levels were determined by Western blotting, using a monoclonal antibody against BAD phosphorylated at serine 112 (23 kDa). An antibody against actin was used to estimate the total amount of protein loaded in each lane of the gel. Graphic bars represent pS122-BAD levels, expressed as arbitrary units relatively to control cells, and are the means AE S.E.M. of four to six independent experiments. (B) The levels of total BAD in neuronal lysates were also determined, using an antibody that recognizes this protein independently of its phosphorylation state (23 kDa). The figure shows a representative blot for BAD, out of four independent experiments. *P < 0.05 compared with control cells in the absence of FK506. similar (qualitatively) to those obtained with Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , in the following studies we used the smaller peptide. BAD levels in the mitochondria of neurons treated with Ab 25-35 (1.24 AE 0.11 a.u.) or PrP 106-126 (1.27 AE 0.15 a.u.) were significantly ( p < 0.05) higher than in control cells (0.98 AE 0.06 a.u.). FK506 prevented the increase of mitochondrial BAD levels induced by the peptides (Fig. 4) , decreasing the levels of this proapoptotic protein to values slightly lower than those observed in untreated cells. These results indicate that CaN mediates BAD translocation to mitochondria in neurons treated with Ab or PrP peptides. In control cells it was also observed a slight effect of FK506 in mitochondrial BAD levels, indicating that, even in untreated neurons, CaN was active and mediated BAD translocation to these organelles. Additionally, it was performed immunocytochemistry studies to confirm that in Aband PrP-treated neurons the BAD is localized in the mitochondria. As can be seen in Fig. 5 an intense colocalization (yellow label) of anti-BAD and MitoTracker green (mitochondria probe) fluorescence was observed in neurons treated with the peptides as compared with control cells, as well as with cells treated with Ab or PrP in the presence of FK506 (Fig. 5 C1) . Thus, these data support that in our experimental conditions Ab and PrP peptides caused BAD translocation to mitochondria, and this can be prevented by calcineurin blockade. Fig. 6 shows that the increase of BAD levels in mitochondria of cells treated with Ab 25-35 and PrP 106-126 peptides (Fig. 4A ) was associated with a decrease in the cytosolic levels of this proapoptotic protein (Fig. 4B) , as well as with a reduction in mitochondrial cyt c levels.
Altogether the data show that Ab and PrP peptides induce CaN overactivation and subsequent BAD dephosphorylation and translocation to mitochondria, where this proapoptotic protein triggers cyt c release. Therefore, the augment in CaN activity induced by these peptides might be responsible for their neurotoxic effects.
Discussion
The involvement of CaN in the neurodegenerative process and memory impairment in AD and PRE remains a controversial issue (Wang et al., 1999; Norris et al., 2005; Biasini et al., 2006; Dineley et al., 2007) . In a previous study we demonstrated that Ab and PrP peptides trigger a caspase-3-dependent apoptotic neuronal death pathway, involving CaN and cyt c release from mitochondria (Agostinho and Oliveira, 2003) . However, in that study, we have not addressed whether these peptides affect the activity and/or expression levels of this Ca 2+ /calmodulin dependent phosphatase 2B.
In the present study we observed that CaN activity was significantly increased in cortical neurons treated with Ab or PrP peptides for 24 h (Fig. 1 ) and 48 h (data not shown). This augment in CaN activity was not correlated with alterations in the levels of this phosphatase (Fig. 2) , but was probably due to an increase in intracellular Ca 2+ concentration triggered by Ab and PrP peptides. In fact, our group has previously shown that Ab and PrP synthetic peptides cause an early increase of intracellular Ca 2+ concentration ([Ca 2+ ] i ) in cortical neurons, which was in part due to Ca 2+ release from endoplasmic reticulum (Agostinho and Oliveira, 2003; Ferreiro et al., 2006) . Although CaN can modulate the activity of voltage-sensitive Ca 2+ channels and endoplasmic reticulum-associated Ca 2+ channels, ryanodine and inositol 1,4,5-triphosphate receptors (Burley and Sihra, 2000; Bultynck et al., 2003) , in our previous study we have shown that the augment of [Ca 2+ ] i caused by Ab and PrP peptides was not affected by the calcineurin inhibitor, FK506 (Agostinho and Oliveira, 2003) . The alterations in Ca 2+ Fig. 4 . Levels of total BAD (phosphorylated and nonphosphorylated) in mitochondria (A) and cytosol (B) of neurons exposed to Ab or PrP. Cultured cortical neurons were treated or not (control) with Ab 25-35 (25 mM) or PrP 106-126 (25 mM) in the presence or absence of FK506 (1 mM), for 24 h. Mitochondrial and cytosolic fractions were obtained after neuronal treatment with peptides and/or FK506. The levels of BAD in these cellular fractions were determined using an antibody that recognizes this propaptotic protein independently of its phosphorylation state (23 kDa). Graphic bars represent BAD levels in mitochondria (A) and in cytosol (B), expressed as arbitrary units, comparing to control cells. The data are means AE S.E.M. of four independent experiments. *P < 0.05 compared with control cells in the absence of FK506, +P < 0.05 compared with the same experimental conditions in the absence of FK506. homeostasis caused by Ab and PrP peptides in cortical neurons were shown to precede reactive oxygen species production (Ferreiro et al., 2006) . Several studies have reported that CaN activity is regulated by Ca 2+ , as well as by oxidative stress conditions (Mansuy, 2003; Celsi et al., 2007) , which are two events that are upregulated in AD and PRE (Hur et al., 2002; LaFerla, 2002) . However, the manner by which Ab and PrP peptides affect CaN remains controversial. A recent study showed that CaN activity was augmented in cortex, hippocampus and cerebellum of transgenic AD animal models, and the accumulation of Ab was coincident with CaN upregulation (Dineley et al., 2007) . Moreover, it was demonstrated that Ab peptides can induce CaN activation, via Ca 2+ influx through a7 nicotinic acetylcholine receptors, in cortical neurons (Snyder et al., 2005) . In the brain of AD patients, CaN was also shown to be upregulated due to its proteolytic cleavage through calpain I activation (Liu et al., 2005) . On the other hand, it was reported that Ab causes downregulation of CaN in a neuronal precursor cell line through the induction of oxidative stress (Celsi et al., 2007) . The discrepancies between this study and others (including our present study) show that Ab peptides upregulate CaN are probably related with differential cell susceptibility and/or peptide exposure (concentration and time period of incubation). Searching the literature, information about the involvement of CaN in PRE falls short. A recent study shows that the activity of this phosphatase was reduced in the cerebellum of a transgenic mouse model of inherited prion disease, but not in hippocampus and cerebral cortex (Biasini et al., 2006) .
Two widely used inhibitors of CaN are FK506 and cyclosporin A (Snyder et al., 1998; Pong and Zaleska, 2003) . In this study we used FK506 because it can cross the blood-brain barrier, unlike cyclosporin A, which is an advantage when the issue is about brain disorders. Our data show that FK506 reduced CaN activity in neurons treated with Ab and PrP peptides (Fig. 1) . Accordingly it was reported that FK506 reduces the activity of this phosphatase in several brain regions of an AD mice model, improving the cognitive deficits observed in these animals (Dineley et al., 2007) .
In order to get more evidence that Ab and PrP peptides upregulate CaN activity we explored the phosphorylation state of its downstream target, BAD. After being dephosphorylated, BAD translocates to mitochondria and promotes the release of cyt c, leading to the activation of an apoptotic caspase cascade (Springer et al., 2000; Kim et al., 2006) . Studies linking CaNmediated BAD dephosphorylation to neurodegeneration triggered by Ab and PrP peptides are lacking. Our data show that cortical neurons treated with Ab or PrP synthetic peptides exhibited lower levels of phospho-BAD (Fig. 3 ) and higher levels of BAD in mitochondria than untreated neurons (Figs. 4 and 5) , and these effects were prevented by the CaN inhibitor, FK506. Moreover, it was shown that in neurons treated with the peptides the increase of mitochondrial BAD levels was parallel to the decrease of cyt c levels (Fig. 6) , indicating that BAD translocation to mitochondria triggers cyt c release that can activate apoptotic neuronal death pathways. These data are in accordance with our previous study showing that FK506 prevents cyt c release from mitochondria, caspase-3 activation and the subsequent apoptotic neuronal death triggered by Ab and PrP peptides (Agostinho and Oliveira, 2003) . Furthermore, it was also demonstrated that CaN activation and BAD dephosphorylation are upstream in premitochondrial signaling events leading to caspase-3 activation in a human teratocarcinoma cell line treated with Ab peptides (Cardoso and Oliveira, 2005) .
Taken together, our data prove that Ab and PrP peptides induce CaN overactivation and, as a consequence, the proapoptotic protein BAD is dephosphorylated and translocated to mitochondria, triggering cyt c release. Cyt c in the cytosol may be responsible for the activation of neuronal apoptotic pathways. Therefore, we can conclude that altered CaN activity is one of the processes that links Ca 2+ dyshomeostasis to neurodegeneration in Alzheimer's and Prion's diseases. Fig. 6 . The increase of BAD levels in mitochondria was associated with a decrease in cytochrome c (cyt c) levels. Mitochondrial fractions of neurons treated or not with Ab 25-35 (25 mM) or PrP 106-126 (25 mM) in the presence or absence of FK506 (1 mM) for 24 h were analyzed by Western blot, using an antibody that recognized total BAD (phospho-independent state) and an antibody that recognized the denaturated form of cyt c (15 kDa). The figure shows a representative Western blot for BAD and cyt c, out of 3 independent experiments.
